Cognition Therapeutics shares rose 30% pre-market after the FDA confirmed its Phase 3 trial for Alzheimer's drug Zervimesine.

Women with Down syndrome have more advanced signs of Alzheimer’s disease than men do, according to research.However, the ...

This insight points to the need for more sex-specific approaches in both Alzheimer’s research and treatment planning, ...

Women with Down syndrome have more advanced signs of Alzheimer's disease than men do at the average age of diagnosis, which ...

A new study by researchers at the University of California, Irvine has revealed that women with Down syndrome exhibit more ...

According to research by the University of California, Irvine, women with Down syndrome have more advanced signs of Alzheimer's disease than men do at the average age of diagnosis, which is the same ...

Cognition Therapeutics Inc (NASDAQ:CGTX) saw its stock jump 27% following FDA confirmation that the company’s proposed Phase ...

Nucleoside reverse transcriptase inhibitor exposure is significantly associated with a reduced risk for subsequent development of Alzheimer Disease, reinforcing the idea that inflammasome inhibition ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer’s development portfolio is being presented at the Alzheimer’s Association ...

In a pre-specified sub-study of the BROADWAY trial, obicetrapib 10 mg significantly reduced plasma p-tau217 levels in patients with ASCVD, including ApoE4 carriers, suggesting dual potential to lower ...

Results from the long-term extension of the Phase III TRAILBLAZER-ALZ 2 trial (NCT04437511) showed sustained benefits with ...